DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rssm7w/hyperphosphatemia) has announced the addition of the "Hyperphosphatemia - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- 3SBio Inc.
- Ardelyx, Inc.
- Galenica Ltd.
- Medice Arzneimittel Putter GmbH & Co. KG
- OPKO Health, Inc.
- Panion & Bf Biotech Inc
- Sanofi
- Spectrum Pharmaceuticals, Inc.
- Toray Industries, Inc.
Drug Profiles
- colestilan chloride
- CPAM-11
- fermagate
- ferric citrate
- calcium succinate
- JPH-101
- niacinamide
- PDX-003
- PT-20
- RDX-002
- sevelamer carbonate
- Small Molecule to Target Phosphate for Hyperphosphatemia
- Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD
- SPI-014
- succharated ferric oxide
- tenapanor hydrochloride
- TRK-390
- VS-501
- VS-505
For more information visit http://www.researchandmarkets.com/research/rssm7w/hyperphosphatemia